Atherothrombotic disease and the role of antiplatelet therapy in women

Journal of Women's Health

Volumn 17, Issue 1, 2008, Pages 35-46

  Grines, Cindy ^a   Cho, Leslie ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIA; LIFESTYLE; LOADING DRUG DOSE; LOW DRUG DOSE; MEDLINE; MENOPAUSE; MONOTHERAPY; OBESITY; PRIORITY JOURNAL; REVIEW; RISK; RISK FACTOR; SEX DIFFERENCE; SMOKING; STENT; STROKE; THROMBOSIS;

ANTICOAGULANTS; ARTERIOSCLEROSIS; ASPIRIN; CLINICAL TRIALS AS TOPIC; EMBOLISM, CHOLESTEROL; FEMALE; HUMANS; HYPERTENSION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; WOMEN'S HEALTH;

EID: 38949184002     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2006.0305     Document Type: Review

References (65)

1. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672.
2. Duvall WL, Vorchheimer DA. Multi-bed vascular disease and atherothrombosis: Scope of the problem. J Thromb Thrombolysis 2004;17:51.
3. American Heart Association. Heart disease and stroke statistics - 2007 update. Available at circ.ahajournals.org Last accessed June 29, 2007.
4. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006;113:2363.
5. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. A statement for healthcare professionals from the American Heart Association Council on Stroke. Stroke 2006;37:577.
6. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991;265:627.
7. O'Sullivan JB, Mahan CM. Mortality related to diabetes and blood glucose levels in a community study. Am J Epidemiol 1982;116:678.
8. Wingard DL, Barrett-Connor E. Heart disease and diabetes. Diabetes in America. Bethesda, MD: National Institutes of Health, NIDDK, 1995.
9. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978;89:157.
10. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981;139:47.
11. Kannel WB. The Framingham Study: Its 50-year legacy and future promise. J Atheroscler Thromb 2000;6:60.
12. Bello N, Mosca L. Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis 2004;46:287.
13. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998;279:1477.
14. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363.
15. Lonn EM, Yusuf S. Evidence based cardiology: Emerging approaches in preventing cardiovascular disease. BMJ 1999;318:1337.
16. Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. Mayo Clin Proc 2005;80:219.
17. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999.
18. Zucker DR, Griffith JL, Beshansky JR, Selker HP. Presentations of acute myocardial infarction in men and women. J Gen Intern Med 1997;12:79.
19. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986;111:383.
20. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N Engl J Med 1984;311:1144.
21. Goldberg RJ, O'Donnell C, Yarzebski J, Bigelow C, Savageau J, Gore JM. Sex differences in symptom presentation associated with acute myocardial infarction: A population-based perspective. Am Heart J 1998;136:189.
22. Marrugat J, Sala J, Masia R, et al. Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera. JAMA 1998;280:1405.
23. Kudenchuk PJ, Maynard C, Martin JS, Wirkus M, Weaver WD. Comparison of presentation, treatment, and outcome of acute myocardial infarction in men versus women (the Myocardial Infarction Triage and Intervention Registry). Am J Cardiol 1996;78:9.
24. Clarke KW, Gray D, Keating NA, Hampton JR. Do women with acute myocardial infarction receive the same treatment as men? BMJ 1994;309:563.
25. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: A report from the National Registry of Myocardial Infarction - I. Arch Intern Med 1998;158:981.
26. Labiche LA, Chan W, Saldin KR, Morgenstern LB. Sex and acute stroke presentation. Ann Emerg Med 2002;40:453.
27. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999;340:618.
28. Harrold LR, Esteban J, Lessard D, et al. Narrowing gender differences in procedure use for acute myocardial infarction: Insights from the Worcester Heart Attack Study. J Gen Intern Med 2003;18:423.
29. Rathore SS, Wang Y, Radford MJ, Ordin DL, Krumholz HM. Sex differences in cardiac catheterization after acute myocardial infarction: The role of procedure appropriateness. Ann Intern Med 2002;137:487.
30. Ghali WA, Faris PD, Galbraith PD, et al. Sex differences in access to coronary revascularization after cardiac catheterization: Importance of detailed clinical data. Ann Intern Med 2002;136:723.
31. Woods KL, Ketley D, Lowy A, et al. Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction. Towards an understanding of factors influencing clinical practice. The European Secondary Prevention Study Group. Eur Heart J 1998;19:74.
32. Herman B, Greiser E, Pohlabeln H. A sex difference in short-term survival after initial acute myocardial infarction. The MONICA-Bremen Acute Myocardial Infarction Register, 1985-1990. Eur Heart J 1997;18:963.
33. Cook NR, Chae C, Mueller FB, Landis S, Saks AM, Hennekens CH. Mis-medication and under-utilization of aspirin in the prevention and treatment of cardiovascular disease. MedGenMed 1999:E1.
34. Schafer AI. Antiplatelet therapy. Am J Med 1996;101:199.
35. Rang HP, Dale MM, Ritter JM. Pharmacology, 4th ed. Oxford: Churchill Livingstone, 1999.
36. Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991;266:521.
37. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293.
38. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306.
39. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706.
40. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71.
41. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329.
42. The CURE trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. N Engl J Med 2001;345:494.
43. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527.
44. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;288:2411.
45. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179.
46. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1607.
47. Diener HC, Bogousslavsky J, Brass LM, et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): Study design and baseline data. Cerebrovasc Dis 2004;17:253.
48. Sivenius J, Laakso M, Penttila IM, Smets P, Lowenthal A, Riekkinen PJ. The European Stroke Prevention Study: Results according to sex. Neurology 1991;41:1189.
49. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1.
50. Iakovou I, Dangas G, Mehran R, et al. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Am J Cardiol 2002;89:976.
51. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002;359:189.
52. Lansky AJ, Pietras C, Costa RA, et al. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2005;111:1611.
53. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997;30:149.
54. PURSUIT. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436.
55. PRISM-PLUS. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488.
56. EPISTENT. Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87.
57. CAPTURE. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429.
58. EPILOG. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336:1689.
59. Braunwald E, Antman EM, Beasley JW, et al. ACC/ AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). Available at www.acc.org/clinical/guidelines/unstable/unstable.pdf Accessed June 30, 2005.
60. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Summary article: A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366.
61. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender: Pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000;36:381.
62. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957.
63. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588.
64. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481.
65. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA 2007;297:2018.